Sök
User Profile
Change
Select your user profile
Artikel

Hepatitis B and C

Committed to effective HCV and HBV diagnosis and monitoring since 1993

Hepatitis B and C are among the most common viral infections in the world. Approximately 328 million people worldwide1,2 are carriers of HBV and HCV infections, which can remain asymptomatic for decades.

Transmission methods

HBV and HCV can be transmitted through various routes, including:1,2

  • Infections by blood transfusion or organ transplants
  • Sex with an infected person
  • Illegal drug usage by sharing needles or syringes
  • Non-sterile equipment (medical, dental, tattoo or body piercings)
  • Sharing of contaminated personal items, like razors or toothbrushes
  • Mother-infant transmissions

 

HBV and HCV leads to 1.4 million deaths every year, more than HIV/AIDS and malaria. Approximately 90% of people living with HBV and 80% of HCV patients are unaware they are infected, which leads to further transmission rates.3

Product portfolios

Kontakta oss
The Global Health Sector Strategy

In 2016, the World Health Assembly adopted WHO’s first “Global Health Sector Strategy on viral hepatitis,” with elimination as its overarching vision.4

Vision

A world where viral hepatitis transmission is halted and everyone living with viral hepatitis has access to safe, affordable and effective prevention, care and treatment services.

Goal

Eliminate viral hepatitis as a major public health threat by 2030.

Targets

  • Between 6 and 10 million infections are reduced to less than 1 million by 2030
  • 1.4 million deaths reduced to less than 500 000 by 2030
90%

reduction in new cases of chronic hepatitis B and C by 2030

65%

reduction in hepatitis-related deaths

80%

of eligible people with chronic hepatitis B and C infections treated by 2030

Algorithm for diagnosis, treatment and monitoring of HBV and HCV

Se hela tabellen
close

Algorithm for diagnosis, treatment and monitoring of HBV and HCV

  Hepatitis B4,5 Hepatitis C4,5
Diagnosis HBsAg
HBeAg
Anti-HBc		 Anti-HCV
HCV RNA
Treatment decision HBV DNA
HBeAg
HBsAg quantification		 HCV genotyping
HCV RNA
On treatment HBV DNA
HBeAg
Anti-HBe		 HCV RNA
End of treatment HBV DNA
HBsAg Quantitative
Anti-HBs
Anti-HBe		 HCV RNA
Follow up HBV DNA
Anti-HBs
Anti-HBe		 HCV RNA
Roche is committed to the elimination of hepatitis

Roche introduced the first-ever test to monitor HCV viral load in 1993 and remains committed to helping eradicate the virus today. Our complete continuum of care for the diagnosis and monitoring of HCV and HBV starts with a focus on serology based testing for screening and diagnosis, followed by PCR testing for confirmation and viral load monitoring to determine patient response to treatment.

You might be interested in

...
    ...